A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy

Kevin Winthrop, Charles L. Daley

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Screening for latent tuberculosis (TB) infection (LTBI) prior to anti-tumor necrosis factor (TNF) therapy is complicated by the decreased sensitivity of the purified protein derivative tuberculin skin test in immunosuppressed patients, as well as the poor specificity of the tuberculin skin test in bacillus Calmette-Guérin (BCG)-vaccinated patients. Interferon-γ-release assays that utilize specific TB antigens (e.g. ESAT-6/CFP-10) have greater specificity for LTBI, but their relative sensitivity is unknown in the setting of immune suppression. Dinser et al. evaluated a novel flow-cytometric interferon-γ detection assay in 97 patients with inflammatory arthritis during LTBI screening for anti-TNF therapy. Overall, 39% of patients had purified protein derivative reactivity in vitro versus 14% cutaneously, and 16% exhibited reactivity in vitro to ESAT-6/CFP-10. The results suggest that flow cytometry using TB-specific antigens might eventually provide another tool for diagnosing LTBI in patients undergoing screening prior to anti-TNF or other immunosuppressive therapies. Further evaluation of the sensitivity and specificity of this novel whole-blood assay is warranted.

Original languageEnglish (US)
Pages (from-to)456-457
Number of pages2
JournalNature Clinical Practice Rheumatology
Volume4
Issue number9
DOIs
StatePublished - 2008

Fingerprint

Latent Tuberculosis
Tumor Necrosis Factor-alpha
Tuberculin Test
Skin Tests
Interferons
Tuberculosis
Therapeutics
Antigens
Tuberculin
Immunosuppressive Agents
Bacillus
Arthritis
Flow Cytometry
Sensitivity and Specificity
Proteins

ASJC Scopus subject areas

  • Rheumatology

Cite this

A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy. / Winthrop, Kevin; Daley, Charles L.

In: Nature Clinical Practice Rheumatology, Vol. 4, No. 9, 2008, p. 456-457.

Research output: Contribution to journalArticle

@article{1eee0c1e954e45468c46924263782e8b,
title = "A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy",
abstract = "Screening for latent tuberculosis (TB) infection (LTBI) prior to anti-tumor necrosis factor (TNF) therapy is complicated by the decreased sensitivity of the purified protein derivative tuberculin skin test in immunosuppressed patients, as well as the poor specificity of the tuberculin skin test in bacillus Calmette-Gu{\'e}rin (BCG)-vaccinated patients. Interferon-γ-release assays that utilize specific TB antigens (e.g. ESAT-6/CFP-10) have greater specificity for LTBI, but their relative sensitivity is unknown in the setting of immune suppression. Dinser et al. evaluated a novel flow-cytometric interferon-γ detection assay in 97 patients with inflammatory arthritis during LTBI screening for anti-TNF therapy. Overall, 39{\%} of patients had purified protein derivative reactivity in vitro versus 14{\%} cutaneously, and 16{\%} exhibited reactivity in vitro to ESAT-6/CFP-10. The results suggest that flow cytometry using TB-specific antigens might eventually provide another tool for diagnosing LTBI in patients undergoing screening prior to anti-TNF or other immunosuppressive therapies. Further evaluation of the sensitivity and specificity of this novel whole-blood assay is warranted.",
author = "Kevin Winthrop and Daley, {Charles L.}",
year = "2008",
doi = "10.1038/ncprheum0865",
language = "English (US)",
volume = "4",
pages = "456--457",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy

AU - Winthrop, Kevin

AU - Daley, Charles L.

PY - 2008

Y1 - 2008

N2 - Screening for latent tuberculosis (TB) infection (LTBI) prior to anti-tumor necrosis factor (TNF) therapy is complicated by the decreased sensitivity of the purified protein derivative tuberculin skin test in immunosuppressed patients, as well as the poor specificity of the tuberculin skin test in bacillus Calmette-Guérin (BCG)-vaccinated patients. Interferon-γ-release assays that utilize specific TB antigens (e.g. ESAT-6/CFP-10) have greater specificity for LTBI, but their relative sensitivity is unknown in the setting of immune suppression. Dinser et al. evaluated a novel flow-cytometric interferon-γ detection assay in 97 patients with inflammatory arthritis during LTBI screening for anti-TNF therapy. Overall, 39% of patients had purified protein derivative reactivity in vitro versus 14% cutaneously, and 16% exhibited reactivity in vitro to ESAT-6/CFP-10. The results suggest that flow cytometry using TB-specific antigens might eventually provide another tool for diagnosing LTBI in patients undergoing screening prior to anti-TNF or other immunosuppressive therapies. Further evaluation of the sensitivity and specificity of this novel whole-blood assay is warranted.

AB - Screening for latent tuberculosis (TB) infection (LTBI) prior to anti-tumor necrosis factor (TNF) therapy is complicated by the decreased sensitivity of the purified protein derivative tuberculin skin test in immunosuppressed patients, as well as the poor specificity of the tuberculin skin test in bacillus Calmette-Guérin (BCG)-vaccinated patients. Interferon-γ-release assays that utilize specific TB antigens (e.g. ESAT-6/CFP-10) have greater specificity for LTBI, but their relative sensitivity is unknown in the setting of immune suppression. Dinser et al. evaluated a novel flow-cytometric interferon-γ detection assay in 97 patients with inflammatory arthritis during LTBI screening for anti-TNF therapy. Overall, 39% of patients had purified protein derivative reactivity in vitro versus 14% cutaneously, and 16% exhibited reactivity in vitro to ESAT-6/CFP-10. The results suggest that flow cytometry using TB-specific antigens might eventually provide another tool for diagnosing LTBI in patients undergoing screening prior to anti-TNF or other immunosuppressive therapies. Further evaluation of the sensitivity and specificity of this novel whole-blood assay is warranted.

UR - http://www.scopus.com/inward/record.url?scp=51149119046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51149119046&partnerID=8YFLogxK

U2 - 10.1038/ncprheum0865

DO - 10.1038/ncprheum0865

M3 - Article

C2 - 18648338

AN - SCOPUS:51149119046

VL - 4

SP - 456

EP - 457

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 9

ER -